Abstract
The data available in the literature on the role of melatonin in the regulation of circadian rhythms and sleep disorders in the population and in patients with mental diseases are analyzed. The cause of insomnia may be circadian rhythm disorders due to the age-related decline in the elaboration of the endogenous hormones that are responsible for the quality and duration of sleep, one of which is melatonin. Sustained-release melatonin is a synthetic analogue of the endogenous human pineal hormone melatonin. According to clinical findings, the main proven clinical effects of sustained-release melatonin 2 mg are a reduction in the latency of sleep, improvement of its quality, and lack of daytime sleepiness. The drug causes no dependence on its long use and rebound symptoms (increased insomnia symptoms), positively affects cognitive functions, and lowers nocturnal blood pressure in hypertensive patients. The paper describes a clinical case of a female patient with recurrent depressive disorder, in whom sustained-release melatonin 2 mg has demonstrated high efficacy and good tolerability in the combination therapy of sleep disorders in the pattern of depression.
Highlights
The data available in the literature on the role of melatonin in the regulation of circadian rhythms and sleep disorders in the population and in patients with mental diseases are analyzed
После возвращения с отдыха перестала принимать пароксетин, считала, что настроение «и так хорошее»
Анализ данных литературы и представленное клиническое наблюдение свидетельствуют о целесообразности применения пролонгированного мелатонина (в дозе 2 мг/сут) для коррекции инсомнии в комплексной терапии депрессивных расстройств
Summary
The data available in the literature on the role of melatonin in the regulation of circadian rhythms and sleep disorders in the population and in patients with mental diseases are analyzed. Что важным патогенетическим фактором развития инсомнии, является снижение выработки эндогенных гормонов, определяющих длительность и качество сна. Впервые циркадин как снотворный препарат для лечения первичной бессонницы с низким качеством сна у пациентов старше 55 лет был зарегистрирован в 2007 г.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.